<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640574</url>
  </required_header>
  <id_info>
    <org_study_id>SMRU1102</org_study_id>
    <nct_id>NCT01640574</nct_id>
  </id_info>
  <brief_title>Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)</brief_title>
  <official_title>Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Southeast Asia, Plasmodium vivax (Pv) infection reaches 50-80% and bears a greater burden
      of disease than Plasmodium falciparum (Pf). As control over Pf improves, Pv will assume
      increasingly larger percentages of malaria prevalence. The chronicity of Pv, due to the
      latent liver stage (hypnozoite) not eradicated by chloroquine, causes recurring disability
      and compounds the economic burden of those with symptomatic disease. The only widely
      available treatment for hypnozoites is primaquine, which, because of challenges with
      tolerability, safety in G6PD deficient persons, and compliance, is not commonly prescribed
      for the treatment of Pv. Currently, chloroquine is used for the treatment of the blood stages
      of Pv, however, there are concerns about increasing parasite resistance. Alternative
      treatments, such as artesunate, should be considered in the future of the treatment of blood
      stage Pv. The use of primaquine in the treatment of hypnozoites (radical cure) should be
      emphasized so that transmission of Pv can be controlled.

      This study aims to determine the optimal primaquine regimen for radical cure of Plasmodium
      vivax. Chloroquine is currently the standard of treatment for Plasmodium vivax. Chloroquine
      may have synergistic effects when used with primaquine and due to its long half-life may
      delay the first relapse of vivax malaria. In contrast, artesunate does not have documented
      interactions with primaquine and has a very short half-life, thus, presumably will have no
      impact on first relapse. Combining primaquine with these two anti-malarials may lead to an
      alternative regimen for Pv infection and changing the primaquine dosing regimen may lead to a
      more practical and efficacious therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of P. vivax</measure>
    <time_frame>52 weeks</time_frame>
    <description>Recurrence with Plasmodium vivax malaria within 52 weeks of first treatment dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Number of adverse events within 28 days of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of P. vivax</measure>
    <time_frame>6 months</time_frame>
    <description>Recurrence with Plasmodium vivax malaria within 6 months of first treatment dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug concentrations</measure>
    <time_frame>63 days</time_frame>
    <description>Chloroquine, piperaquine and primaquine drug levels</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">680</enrollment>
  <condition>Vivax Malaria</condition>
  <arm_group>
    <arm_group_label>DHA-P 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHA-P 14 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine 7 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine 14 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin-Piperaquine</intervention_name>
    <description>Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days</description>
    <arm_group_label>DHA-P 7 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin-Piperaquine</intervention_name>
    <description>Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days</description>
    <arm_group_label>DHA-P 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days</description>
    <arm_group_label>Chloroquine 7 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days</description>
    <arm_group_label>Chloroquine 14 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 6 months old

          -  Microscopic diagnosis of Plasmodium vivax malaria mono-infection

          -  Participant or parent/guardian is willing and able to give informed consent for
             participation in the study

          -  Able (in the Investigators opinion) and willing to comply with all study requirements.

        Exclusion Criteria:

          -  Severe malaria

          -  History of allergy or adverse reaction to artesunate, piperaquine, chloroquine, or
             primaquine

          -  Blood transfusion in the past 3 months

          -  G6PD deficiency by rapid test

          -  Hematocrit ≤ 25%

          -  Pregnancy at the time of screening

          -  Breastfeeding an infant &lt; 6 months old

          -  Presence of any condition which in the judgement of the investigator would place the
             subject at undue risk or interfere with the results of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Nosten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cindy Chu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shoklo Malaria Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shoklo Malaria Research Unit</name>
      <address>
        <city>Mae Sot</city>
        <state>Tak</state>
        <zip>63110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <last_update_submitted>April 27, 2016</last_update_submitted>
  <last_update_submitted_qc>April 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vivax</keyword>
  <keyword>Chloroquine</keyword>
  <keyword>Primaquine</keyword>
  <keyword>Dihydroartemisinin-Piperaquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

